Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4269/ajtmh.20-1294 http://scihub22266oqcxt.onion/10.4269/ajtmh.20-1294 33200726!7790086!33200726     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33200726&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Am+J+Trop+Med+Hyg 2021 ; 104 (1): 32-34 Nephropedia Template TP {{tp|p=33200726|t=2021. Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials |pdf=|usr=}}{{33200726}} gab.com Text Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials JO: Am J Trop Med Hyg http://www.kidney.de/pget.php?&tw=1&pmid=33200726 #FOAvip Minority communities have borne the brunt of COVID-19 disease in the United States. Nonwhites have contracted most of the SARS-CoV-2 infections; COVID-19 mortality rates for Black Americans are more than twice those for whites. Given this, studying the most effective ways to prevent and treat SARS-CoV-2 in these populations should be a research priority, particularly with respect to vaccine trials. Federal guidelines from the National Institutes of Health and Food and Drug Administration emphasize the need for inclusion of minority groups in these trials, but none of the publicly available SARS-CoV-2 vaccine trial protocols requires representative sampling of minorities. This piece emphasizes the importance of adequate inclusion of minority communities in SARS-CoV-2 vaccine trials, and the implications of this inclusion for SARS-CoV-2 vaccine distribution. Twit Text FOAVip Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials ????Am J Trop Med Hyg http://www.kidney.de/pget.php?&tw=1&pmid=33200726 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33200726 #FOAvip English Wikipedia <ref>{{Cite pmid|33200726}}</ref> Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials #MMPMID33200726 Craft JF; Travassos MA; Foppiano Palacios C; Openshaw JJ Am J Trop Med Hyg 2021[Jan]; 104 (1): 32-34 PMID33200726show ga Minority communities have borne the brunt of COVID-19 disease in the United States. Nonwhites have contracted most of the SARS-CoV-2 infections; COVID-19 mortality rates for Black Americans are more than twice those for whites. Given this, studying the most effective ways to prevent and treat SARS-CoV-2 in these populations should be a research priority, particularly with respect to vaccine trials. Federal guidelines from the National Institutes of Health and Food and Drug Administration emphasize the need for inclusion of minority groups in these trials, but none of the publicly available SARS-CoV-2 vaccine trial protocols requires representative sampling of minorities. This piece emphasizes the importance of adequate inclusion of minority communities in SARS-CoV-2 vaccine trials, and the implications of this inclusion for SARS-CoV-2 vaccine distribution. |*Minority Groups[MESH] |American Indian or Alaska Native[MESH] |Black or African American[MESH] |COVID-19 Vaccines/*immunology[MESH] |COVID-19/*epidemiology/*prevention & control[MESH] |Clinical Trials as Topic/*organization & administration/standards[MESH] |Ethnicity/statistics & numerical data[MESH] |Healthcare Disparities[MESH] |Hispanic or Latino[MESH] |Humans[MESH] |Research Design[MESH] |SARS-CoV-2/*immunology[MESH]Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials (epmc).pdf DeepDyve Pubget Overpricing